Keay Nakae
Stock Analyst at Chardan Capital
(4.20)
# 462
Out of 5,026 analysts
252
Total ratings
42.91%
Success rate
18.85%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
MNPR Monopar Therapeutics | Maintains: Buy | $60 → $85 | $82.56 | +2.96% | 4 | Sep 25, 2025 | |
SABS SAB Biotherapeutics | Maintains: Buy | $12 | $2.17 | +453.00% | 17 | Sep 19, 2025 | |
COYA Coya Therapeutics | Maintains: Buy | $14 | $6.30 | +122.22% | 21 | Sep 17, 2025 | |
RNA Avidity Biosciences | Maintains: Buy | $75 | $48.78 | +53.75% | 19 | Sep 10, 2025 | |
OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $3.68 | +443.48% | 12 | Aug 13, 2025 | |
KRRO Korro Bio | Maintains: Buy | $25 | $48.60 | -48.56% | 3 | Aug 13, 2025 | |
ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $38.97 | +53.96% | 20 | Aug 11, 2025 | |
ABUS Arbutus Biopharma | Maintains: Buy | $5 | $4.51 | +10.86% | 13 | Aug 11, 2025 | |
PRQR ProQR Therapeutics | Maintains: Buy | $4 | $2.80 | +42.86% | 15 | Aug 8, 2025 | |
SLN Silence Therapeutics | Maintains: Buy | $35 | $6.59 | +431.11% | 13 | Aug 8, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $400 | $481.07 | -16.85% | 14 | Aug 1, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $38 | $16.42 | +131.43% | 13 | Jul 29, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $0.85 | +491.37% | 5 | Jun 25, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $19.26 | -68.85% | 10 | May 8, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $3.73 | +436.19% | 14 | Apr 7, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.81 | +231.49% | 7 | Mar 28, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2.5 | $2.03 | +23.15% | 6 | Mar 27, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.75 | +973.25% | 10 | Nov 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.70 | - | 5 | Feb 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $18.09 | -66.83% | 7 | Aug 4, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $20 | $0.59 | +3,285.81% | 4 | Nov 10, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $9.40 | +485.11% | 10 | Nov 9, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $4.90 | +104.08% | 5 | Aug 16, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $11.96 | +631.61% | 2 | Sep 20, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.61 | +707.45% | 3 | Feb 9, 2021 |
Monopar Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $60 → $85
Current: $82.56
Upside: +2.96%
SAB Biotherapeutics
Sep 19, 2025
Maintains: Buy
Price Target: $12
Current: $2.17
Upside: +453.00%
Coya Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $14
Current: $6.30
Upside: +122.22%
Avidity Biosciences
Sep 10, 2025
Maintains: Buy
Price Target: $75
Current: $48.78
Upside: +53.75%
Orchestra BioMed Holdings
Aug 13, 2025
Maintains: Buy
Price Target: $20
Current: $3.68
Upside: +443.48%
Korro Bio
Aug 13, 2025
Maintains: Buy
Price Target: $25
Current: $48.60
Upside: -48.56%
Arrowhead Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $60
Current: $38.97
Upside: +53.96%
Arbutus Biopharma
Aug 11, 2025
Maintains: Buy
Price Target: $5
Current: $4.51
Upside: +10.86%
ProQR Therapeutics
Aug 8, 2025
Maintains: Buy
Price Target: $4
Current: $2.80
Upside: +42.86%
Silence Therapeutics
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $6.59
Upside: +431.11%
Aug 1, 2025
Maintains: Buy
Price Target: $325 → $400
Current: $481.07
Upside: -16.85%
Jul 29, 2025
Maintains: Buy
Price Target: $50 → $38
Current: $16.42
Upside: +131.43%
Jun 25, 2025
Maintains: Buy
Price Target: $5
Current: $0.85
Upside: +491.37%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $19.26
Upside: -68.85%
Apr 7, 2025
Maintains: Buy
Price Target: $20
Current: $3.73
Upside: +436.19%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $1.81
Upside: +231.49%
Mar 27, 2025
Maintains: Neutral
Price Target: $2.5
Current: $2.03
Upside: +23.15%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.75
Upside: +973.25%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.70
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $18.09
Upside: -66.83%
Nov 10, 2022
Maintains: Buy
Price Target: $60 → $20
Current: $0.59
Upside: +3,285.81%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $9.40
Upside: +485.11%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $4.90
Upside: +104.08%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $11.96
Upside: +631.61%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.61
Upside: +707.45%